Objective To observe the effect of simvastatin combined with alendronate sodium in treating alcohol-induced avascular necrosis of femoral head (AIANFH) and its impact on toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB) pathway.
Methods A total of 90 patients with AIANFH were selected and divided into observation group and control group, with 45 cases in each group. The control group was treated with alendronate sodium orally, and the observation group was addtionally given simvastatin. The course of treatment was 3 months. The excellent rate of hip joints and incidence of adverse reactions after treatment of two groups were compared, and serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), adiponectin, osteocalcin and the mRNA expressions of TLR4 and NF-κB p65 in peripheralblood mononuclear cells (PBMC) were compared between the two groups before and after treatment.
Results The excellent rate of hip joints in observation group was higher than that in the control group (91.11% versus 75.56%, P < 0.05). After treatment, serum TNF-α, IL-1β, and IL-6 levels of two groups were significantly lower than treatment before, and serum adiponectin and osteocalcin were increased (P < 0.05). After treatment, expressions of TLR4 mRNA and NF-κB p65 mRNA of PBMC in two groups were decreased, and the were lower in the observation group than those in the control group (P < 0.05). The total incidence of adverse reactions in the observation group and the control group were 24.44% and 15.56%, but no differences were found(P>0.05).
Conclusion Simvastatin combined with alendronate sodium can inhibit the TLR4/NF-κB signaling pathway, inhibit inflammation, and up-regulate the levels of adiponectin and osteocalcin, and it has higher safety.
DownLoad: